Abstract
Objective: The study aims to explore the human in vivo metabolism of SEP-227900 (4H-furo[3, 2-b] pyrrole-carboxylic acid, m.w 151.03), a D-amino-acid oxidase (DAAO) inhibitor, by using plasma and urine samples from first-in-human study.
Methods: The human plasma and urine samples were from a single dose cohort that consisted of 9 healthy male volunteers each received an 80- mg dose of SEP-227900 orally. The pooled pre-dose urine and the pooled 0-24 h urine sample were created across 9 subjects by equal volume. Plasma samples were pooled by equal volume across 9 subjects to obtain 0-12 h plasma for metabolite searching, and also pooled by timepoints across 9 subjects to obtain 0.5, 5, and 12-h plasma for semi-quantitation. The plasma was de-proteinized by acetonitrile (1:3 v/v plasma-acetonitrile), then the supernatant was dried down, reconstituted, and injected for LC-HRMS/UV analysis. The urine sample was just simply centrifuged before analysis. LC-HRMS/UV was utilized to search predictable and unknown metabolites and estimate their relative abundances. Accurate mass measurement by Orbitrap-MS and MS/MS was used for metabolite identification. Chromatographic separation was achieved on a MACMOD AQ C8 column (250 × 4.6 mm, 5-μm) with a gradient mobile phase (A: 10 mM NH4Ac; B: acetonitrile; flowrate: 0.700 ml/min) for a total run-time of 65 min. The definite position in the molecule for the glucuronidation metabolism was characterized by the detected migration phenomenon, methylation with diazomethane (CH2N2), and NMR.
Results: Unchanged parent drug and four metabolite peaks were detected in humans: M1 was a mono-oxidative metabolite of SEP-227900; M2 was a glucuronide conjugate of SEP-227900; M3 was a glycine conjugate of SEP-227900; M4 was a glycine conjugate of M1. The specific position of the oxidation in M1 solely based on the mass spectral (MS and MS/MS) data was not identified. However, for the major metabolite M2, the acyl glucuronidation was unambiguously determined through multiple pieces of experimental evidence such as the observation of a migration pattern, mono-methylation by diazomethane, and NMR measurement. This determination is of significance related to the safety evaluation of investigational new drug development. The glycine conjugate of SEP-227900, i.e., M3, was found to be the most abundant metabolite in human urine (approximately 3-fold higher level than the glucuronide level). All together (mainly glycine-conjugate and glucuronide), it resulted in greater than 80% of the dosed amount in urine excretion (a separate measurement showed 23% of the dosed amount in urine excretion as the glucuronide).
Conclusion: Four metabolites were found in humans: SEP-227900-glycine conjugate, SEP- 227900-glucuronide, mono-oxidative metabolite, and its consequent glycine conjugate. The glucuronide metabolite was identified as acyl glucuronide. Greater than 80% of the dosed amount of SEP-227900 was excreted in the urine, mainly in the forms of glycine- and glucuronide- conjugates.
Keywords: SEP-227900, D-amino-acid oxidase (DAAO) inhibitor, drug metabolism, acyl glucuronide, LC-HRMS/UV, NMR.
Graphical Abstract
[http://dx.doi.org/10.1007/s40122-017-0087-0] [PMID: 29178033]
[http://dx.doi.org/10.1503/cmaj.060146] [PMID: 16880448]
[http://dx.doi.org/10.1111/j.1526-4637.2006.00179.x] [PMID: 17714116]
[http://dx.doi.org/10.1517/14728214.10.1.95] [PMID: 15757406]
[http://dx.doi.org/10.1146/annurev.med.57.121304.131324] [PMID: 16409165]
[http://dx.doi.org/10.1007/s11916-007-0192-6] [PMID: 17504648]
[http://dx.doi.org/10.1212/01.wnl.0000259085.61898.9e] [PMID: 17420400]
[http://dx.doi.org/10.1016/S0306-3623(96)00359-X] [PMID: 9184794]
[http://dx.doi.org/10.1016/j.bbrc.2006.02.156] [PMID: 16546123]
[http://dx.doi.org/10.1016/S0009-2797(03)00020-6] [PMID: 12686489]
[http://dx.doi.org/10.3109/03602539208996289] [PMID: 1555494]
[http://dx.doi.org/10.1097/00007691-200302000-00001] [PMID: 12548138]
[http://dx.doi.org/10.1016/j.dmpk.2016.11.002] [PMID: 28017536]
[http://dx.doi.org/10.1016/j.toxlet.2017.03.003] [PMID: 28286018]
[http://dx.doi.org/10.1124/dmd.115.066159] [PMID: 26276581]
[http://dx.doi.org/10.1042/bj1200891] [PMID: 5500354]
[http://dx.doi.org/10.1002/jms.1607] [PMID: 19536806]
[http://dx.doi.org/10.3109/03602538409033562] [PMID: 6396057]
[http://dx.doi.org/10.1124/jpet.104.068536] [PMID: 15194707]
[http://dx.doi.org/10.1038/clpt.2014.141] [PMID: 24971633]
[http://dx.doi.org/10.1016/0006-2952(93)90480-K] [PMID: 8216382]
[http://dx.doi.org/10.1016/j.dmpk.2017.10.002] [PMID: 29079228]
[http://dx.doi.org/10.1517/17425255.2013.796929] [PMID: 23650932]
[http://dx.doi.org/10.17145/jab.19.005]
[http://dx.doi.org/10.1517/13543784.2015.1099627] [PMID: 26472477]
[http://dx.doi.org/10.1038/clpt.1981.56] [PMID: 6781809]
[http://dx.doi.org/10.1021/js970486q] [PMID: 9649361]
[http://dx.doi.org/10.1002/prp2.281] [PMID: 28596833]